eagle-i University of Hawaii at ManoaUniversity of Hawaii at Manoa
See it in Search
This page is a preview of the following resource. Continue onto eagle-i search using the button on the right to see the full record.

Randomized, double-blind, placebo-controlled phase III trial to evaluate the effectiveness of a phosphodiesterase 5 inhibitor, tadalafil, in prevention of erectile dysfunction in patients treated with radiotherapy for prostate cancer

eagle-i ID


Resource Type

  1. Clinical trial


  1. ClinicalTrials.gov url
  2. Intervention
  3. Resource Description
    RATIONALE: Tadalafil may help prevent erectile dysfunction in patients with prostate cancer that have been treated with radiation therapy. It is not yet known whether tadalafil is more effective than a placebo in preventing erectile dysfunction. PURPOSE: This randomized phase III trial is studying tadalafil to see how well it works compared with a placebo in preventing erectile dysfunction in patients with prostate cancer treated with radiation therapy.
  4. Contact
    Berenberg, Jeffrey
  5. PI
    Berenberg, Jeffrey
  6. Topic
    prostate cancer
  7. Study Population
    Males age 18 and older with diagnosis of adenocarcinoma of the prostate within the past 6 months.
  8. Website(s)
  9. Funded by
    Radiation Therapy Oncology Group
  10. Phase
    Phase 3 clinical trial
  11. Performed by
    Clinical Protocol & Data Management Shared Resource
Provenance Metadata About This Resource Record
Copyright © 2016 by the President and Fellows of Harvard College
The eagle-i Consortium is supported by NIH Grant #5U24RR029825-02 / Copyright 2016